Takeda S, Takada S, Kojima T, Kinoshita K, Sakamoto S
Department of Obstetrics and Gynecology, Saitama Medical Center, Saitama Medical School.
Nihon Gan Chiryo Gakkai Shi. 1990 Oct 20;25(10):2562-6.
Seven patients with Stage III-IV ovarian carcinoma were treated with oral etoposide. The patients received a dose of 25 or 50 mg/day/body for every day or 21 consecutive days every one months. Four patients received this treatment as second line chemotherapy, two as initial chemotherapy and one as maintenance chemotherapy. One of 6 patients with measurable tumor had complete response, one had partial response and four had no changes. One patient with embryonal carcinoma, who received this treatment as maintenance chemotherapy is in no relapse for 2 years and 2 months. Leucopenia with a WBC under 3,000/mm3 was seen in 3 cases. Oral mucositis occurred in 2 cases, hair loss and gastrointestinal toxicities in 1 case. This method of oral administration is effective, tolerated and convenient for advanced ovarian carcinoma and recurrence following prior, vigorous chemotherapy in a outpatient clinic.
7例Ⅲ-Ⅳ期卵巢癌患者接受了口服依托泊苷治疗。患者每1个月连续21天每天接受25或50mg/日/体的剂量。4例患者接受此治疗作为二线化疗，2例作为初始化疗，1例作为维持化疗。6例可测量肿瘤患者中1例完全缓解，1例部分缓解，4例无变化。1例胚胎癌患者接受此治疗作为维持化疗，2年2个月无复发。3例出现白细胞减少，白细胞计数低于3000/mm³。2例发生口腔黏膜炎，1例出现脱发和胃肠道毒性。这种口服给药方法对晚期卵巢癌以及先前进行过积极化疗后的复发患者有效、耐受性好且方便在门诊使用。
